Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough

Is the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) associated with increased risk of chronic cough?In this cohort study of 427 555 individuals who were prescribed a GLP-1RA and 1 614 495 matched individuals who were prescribed a different second-line diabetes medication, GLP-1RA treatment was associated with a higher adjusted hazard ratio of new chronic cough. This association was independent of gastroesophageal reflux disease diagnosis.The study findings suggest that patients who use GLP-1RAs have an increased risk of chronic cough, suggesting further exploration of the strength of this association and pharmacologic mechanisms.

Corresponding Author: Anca M. Barbu, MD, 8631 W 3rd St, Medical Offices East, Suite 915E, Los Angeles CA, 90048 (anca.barbu@cshs.org)

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.